Fortrea Holdings Inc.
Financials
Valuation Metrics
Fortrea Holdings Inc.'s Market Cap is $1.89B. At end of 2025 it was $1.57B. Ranked #1964 of 3,118 in US market (top 63%), #732 of 1,474 on NASDAQ (top 50%), #134 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 51%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.89B | US#1,964/3,118 Sec#134/265 |
| Revenue | $2.67B | US#1,254/3,118 Sec#34/265 |
| Net Income | $-69M | US—/3,118 Sec—/265 |
| Total Assets | $2.74B | US#1,880/3,118 Sec#48/265 |
| Net Assets | $532M | US#2,199/3,118 Sec#104/265 |
| Employees | 13,871 | US#713/3,118 Sec#23/265 |
| Value | ||
| P/B | 3.56x | US#2,028/3,118 Sec#121/265 |
| P/S | 0.71x | US#523/3,118 Sec#8/265 |
| EV/EBITDA | 26.76x | US#2,290/3,118 Sec#66/265 |
| FCF Yield | 6.53% | US#917/3,118 Sec#28/265 |
| Profitability | ||
| ROE | -12.91% | US#2,439/3,118 Sec#95/265 |
| ROA | -2.51% | US#2,439/3,118 Sec#80/265 |
| Op. Margin | 1.57% | US#2,297/3,118 Sec#78/265 |
| Revenue Growth | -3.38% | US#2,324/3,118 Sec#136/265 |
| Financial Health | ||
| Debt Ratio | 414.41% | US#2,283/3,118 Sec#220/265 |
| Total Debt | $1.12B | US#1,460/3,118 Sec#44/265 |
| FCF | $124M | US#1,534/3,118 Sec#56/265 |
| Cash | $221M | US#1,861/3,118 Sec#124/265 |
| Current Ratio | 0.97x | US#2,324/3,118 Sec#255/265 |
| Net Debt/EBITDA | 8.61x | US#2,395/3,118 Sec#83/265 |
| Dividend | ||
| Div. Yield | 0.00% | US—/3,118 Sec—/265 |
| Payout Ratio | 0.00% | US—/3,118 Sec—/265 |
| Performance | ||
| 1Y Return | 91.35% | US#110/3,118 Sec#27/265 |
| 1M Return | 0.08% | US#1,069/3,118 Sec#68/265 |
| From 52W High | -23.49% | US#1,404/3,118 Sec#78/265 |
| 1Y MDD | -51.47% | US#2,448/3,118 Sec#171/265 |
| Trading | ||
| Volume | 1,498,508 shares | US#772/3,118 Sec#64/265 |
| Trading Value | $31M | US#1,219/3,118 Sec#72/265 |
| Per Share | ||
| EPS | $-0.73 | US—/3,118 Sec—/265 |
| BPS | $5.63 | US#2,230/3,118 Sec#120/265 |
Company Info
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.